Dyne Therapeutics (DYN) Competitors $11.76 -0.58 (-4.70%) Closing price 04:00 PM EasternExtended Trading$11.66 -0.11 (-0.89%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. NUVL, ADMA, PCVX, RYTM, KRYS, SRPT, PTCT, ACAD, CYTK, and RNAShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Nuvalent (NUVL), ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Nuvalent ADMA Biologics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech Sarepta Therapeutics PTC Therapeutics ACADIA Pharmaceuticals Cytokinetics Avidity Biosciences Nuvalent (NASDAQ:NUVL) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has more volatility and risk, NUVL or DYN? Nuvalent has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Does the media prefer NUVL or DYN? In the previous week, Nuvalent had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 13 mentions for Nuvalent and 11 mentions for Dyne Therapeutics. Nuvalent's average media sentiment score of 1.61 beat Dyne Therapeutics' score of 1.45 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyne Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NUVL or DYN more profitable? Nuvalent's return on equity of -28.63% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -28.63% -27.15% Dyne Therapeutics N/A -57.46%-51.62% Which has higher valuation and earnings, NUVL or DYN? Nuvalent is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$126.22M-$4.39-16.78Dyne TherapeuticsN/AN/A-$235.94M-$3.59-3.28 Do analysts recommend NUVL or DYN? Nuvalent currently has a consensus target price of $115.50, indicating a potential upside of 56.80%. Dyne Therapeutics has a consensus target price of $47.25, indicating a potential upside of 301.79%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.07 Does the MarketBeat Community favor NUVL or DYN? Dyne Therapeutics received 1 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 77.97% of users gave Dyne Therapeutics an outperform vote. CompanyUnderperformOutperformNuvalentOutperform Votes4578.95% Underperform Votes1221.05% Dyne TherapeuticsOutperform Votes4677.97% Underperform Votes1322.03% Do insiders and institutionals have more ownership in NUVL or DYN? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 12.5% of Nuvalent shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryNuvalent and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-3.308.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book7.896.466.794.50Net Income-$235.94M$143.98M$3.23B$248.18M7 Day Performance0.51%3.04%4.07%1.14%1 Month Performance26.05%7.44%12.52%15.20%1 Year Performance-63.96%-2.46%16.83%6.56% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.7712 of 5 stars$11.76-4.7%$47.25+301.8%-65.1%$1.34BN/A-3.30100Positive NewsGap DownNUVLNuvalent2.6421 of 5 stars$73.310.0%$115.50+57.6%+7.0%$5.25BN/A-21.1340News CoveragePositive NewsADMAADMA Biologics3.1796 of 5 stars$20.19+2.5%$24.25+20.1%+117.2%$4.82B$459.38M72.11530News CoveragePositive NewsGap DownPCVXVaxcyte3.0977 of 5 stars$32.03+0.6%$136.50+326.2%-51.8%$4.13BN/A-6.96160News CoveragePositive NewsEarnings ReportRYTMRhythm Pharmaceuticals3.9119 of 5 stars$61.25+2.2%$75.38+23.1%+63.9%$3.90B$136.86M-14.15140KRYSKrystal Biotech4.8578 of 5 stars$132.29+1.3%$211.13+59.6%-20.0%$3.82B$333.45M44.24210SRPTSarepta Therapeutics4.8318 of 5 stars$37.94+4.1%$124.36+227.8%-69.4%$3.73B$2.23B30.35840Positive NewsAnalyst ForecastGap UpHigh Trading VolumePTCTPTC Therapeutics4.1851 of 5 stars$46.96+2.1%$61.92+31.9%+17.6%$3.72B$1.77B-7.911,410ACADACADIA Pharmaceuticals3.2836 of 5 stars$21.99-1.2%$25.42+15.6%+43.6%$3.68B$996.28M28.19510Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeCYTKCytokinetics4.1484 of 5 stars$30.75-0.8%$74.44+142.1%-46.1%$3.67B$19.22M-5.72250RNAAvidity Biosciences1.908 of 5 stars$30.22-0.4%$66.38+119.7%+8.2%$3.64B$8.93M-10.49190Options Volume Related Companies and Tools Related Companies Nuvalent Competitors ADMA Biologics Competitors Vaxcyte Competitors Rhythm Pharmaceuticals Competitors Krystal Biotech Competitors Sarepta Therapeutics Competitors PTC Therapeutics Competitors ACADIA Pharmaceuticals Competitors Cytokinetics Competitors Avidity Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
